165 related articles for article (PubMed ID: 38088015)
1. Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives.
Kato T; Casarini I; Cobo M; Faivre-Finn C; Hegi-Johnson F; Lu S; Özgüroğlu M; Ramalingam SS
Lung Cancer; 2024 Jan; 187():107414. PubMed ID: 38088015
[TBL] [Abstract][Full Text] [Related]
2. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
Naidoo J; Antonia S; Wu YL; Cho BC; Thiyagarajah P; Mann H; Newton M; Faivre-Finn C
J Thorac Oncol; 2023 May; 18(5):657-663. PubMed ID: 36841540
[TBL] [Abstract][Full Text] [Related]
3. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
4. A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial).
Choi J; Lee JE; Choi CM; Oh IJ; Lee KY; Jang TW; Lee SH; Kim EY; Park DW; Park SH; Lee SY
Thorac Cancer; 2022 Dec; 13(23):3431-3435. PubMed ID: 36259253
[TBL] [Abstract][Full Text] [Related]
5. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.
Frampton JE
Target Oncol; 2022 May; 17(3):369-376. PubMed ID: 35713772
[TBL] [Abstract][Full Text] [Related]
6. Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.
Agulnik JS; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Small D
Curr Oncol; 2021 Dec; 28(6):5179-5191. PubMed ID: 34940073
[TBL] [Abstract][Full Text] [Related]
7. Role of immunotherapy in metastatic EGFRm NSCLC: Is it relevant?
Dhabhar B; Sahoo TP; Akshay JK
Indian J Cancer; 2022 Mar; 59(Supplement):S68-S79. PubMed ID: 35343192
[TBL] [Abstract][Full Text] [Related]
8. Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.
Nindra U; Shahnam A; Stevens S; Pal A; Nagrial A; Lee J; Yip PY; Adam T; Boyer M; Kao S; Bray V
Asia Pac J Clin Oncol; 2024 Feb; 20(1):16-24. PubMed ID: 36855021
[TBL] [Abstract][Full Text] [Related]
9. Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study.
Subramanian J; Leighl NB; Choi YL; Chou TY; Gregg J; Hui R; Marchetti A; Silvey M; Makin R; Gillespie-Akar L; Taylor A; Kahangire DA; Bailey T; Chau M; Navani N
Lung Cancer; 2023 Jan; 175():47-56. PubMed ID: 36455396
[TBL] [Abstract][Full Text] [Related]
10. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
Lu S; Shih JY; Jang TW; Liam CK; Yu Y
Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
[TBL] [Abstract][Full Text] [Related]
12. Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer.
Aredo JV; Wakelee HA; Hui AB; Padda SK; Joshi ND; Guo HH; Chaudhuri A; Diehn M; Loo BW; Neal JW
Cancer Treat Res Commun; 2022; 33():100659. PubMed ID: 36427429
[TBL] [Abstract][Full Text] [Related]
13. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
Sun JM; Park K
Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
[TBL] [Abstract][Full Text] [Related]
14. Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs.
Arrieta O; Hernandez-Martinez JM; Montes-Servín E; Heredia D; Cardona AF; Molina-Romero C; Lara-Mejía L; Diaz-Garcia D; Bahena-Gonzalez A; Mendoza-Oliva DL
Cancer Biomark; 2021; 32(2):123-135. PubMed ID: 34057135
[TBL] [Abstract][Full Text] [Related]
15. [Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis].
Xu HY; Chen HQ; Kong JX; Zhang Y; Liu S; Yang GJ; Wang Y
Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):399-405. PubMed ID: 35144338
[No Abstract] [Full Text] [Related]
16. Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study.
Jazieh AR; Onal HC; Tan DS; Soo RA; Prabhash K; Kumar A; Huggenberger R; Cho BC
Ther Adv Med Oncol; 2022; 14():17588359221122720. PubMed ID: 36119641
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
18. Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC.
Hellyer JA; Aredo JV; Das M; Ramchandran K; Padda SK; Neal JW; Wakelee HA
J Thorac Oncol; 2021 May; 16(5):868-872. PubMed ID: 33539970
[TBL] [Abstract][Full Text] [Related]
19. Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?
Desai S; Kim C; Veytsman I
Curr Oncol Rep; 2019 Aug; 21(9):84. PubMed ID: 31410582
[TBL] [Abstract][Full Text] [Related]
20. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
